Prof. Rabia Kahveci, MD

Dr. Rabia Kahveci is MSH’s senior technical advisor for pharmaceutical policy and governance, where she currently serves on the USAID SAFE and Affordable Medicines for Ukrainians (SAFEMed) activity. A medical doctor with a degree in health technology assessment (HTA), Dr. Kahveci has authored more than 150 peer-reviewed journal articles and eight books and has delivered more than 300 scientific presentations at international meetings on HTA. Prior to joining MSH, Dr. Kahveci was the director of the Health Technology Assessment Unit at Ankara Numune Training and Research Hospital in Ankara, Turkey and a professor of family medicine at the same hospital. She contributed to numerous national and international projects around HTA, including the European Network for Health Technology Assessment (EUnetHTA) and Adopting Hospital-Based Health Technology Assessment (AdHopHTA). In 2017, Dr. Kahveci served as the national clinical quality coordinator of the Turkish Ministry of Health, where she coordinated all activities involving HTA, clinical guidelines, and quality.

Dr. Kahveci’s previous roles include serving on the Pharmaceuticals Reimbursement Committee of the Turkish Social Security Institution during the transition to universal health coverage, and she co-authored reimbursement guidelines. She worked at the Turkish Medicines Agency on pricing and reimbursement of pharmaceuticals and led the agency’s HTA work.

Dr. Kahveci is vice president (2021–23) and president-elect (2023–25) of International Health Technology Assessment (HTAi), a nonprofit organization dedicated to fostering health technology assessments worldwide, where she previously served as a board member, chair of the Developing Countries Interest Group, co-chair of the Medical Devices Interest Group, and chair or member of various HTAi committees.